Combined Trial Reviews To Become The Norm In UK From 2022
Executive Summary
Having gained enough experience with the combined ethics and regulatory review of clinical trial applications, the UK will make this its only route for evaluating new drug trial applications starting next year.
You may also be interested in...
UK Tests Streamlined Assessment Of Requests For Trials Involving Drugs & Devices
A new UK pilot involves co-ordinated reviews by the medicine and medical device divisions of the UK MHRA, as well as the research ethics committee.
UK Tests Streamlined Assessment Of Requests For Trials Involving Drugs And Devices
A new UK pilot involves co-ordinated reviews by the medicine and medical device divisions of the UK MHRA, as well as the research ethics committee.
UK Kicks Off Landmark Overhaul Of Clinical Trial Framework
The UK regulatory agency, the MHRA, is planning to establish a “world-class sovereign regulatory environment” for clinical trials to support the development of new innovative medicines. In the first of two articles, we look at the MHRA’s proposals to slim down trial approval processes, lighten the safety reporting burden, and introduce greater transparency of trial registration and results.